Mr. Pennachio called for federal and state governments to use HCQ to tackle the spread of COVID-19, the illness caused by the novel coronavirus, in response to a peer-reviewed study by French infectious disease specialist Didier Raoult, MD, PhD.
In the study, Dr. Raoult demonstrated positive results for the treatment of COVID-19 with HCQ, which has the ability to prevent the virus from entering the cell as well as reproducing.
Dr. Raoult found a substantial decrease in “viral shedding” from patients treated with HCQ, which reduces the likelihood of the virus being transmitted to others.
HCQ also has a 22-day half-life within the body, reinforcing its efficacy for the treatment of COVID-19.
More articles on practice management:
NuVasive recalls Magec system for scoliosis, advises surgeons to perform clinical follow-ups
Zimmer Biomet asks European hospitals to remove orthopedic spacer molds
Resurgens Orthopaedics postpones elective surgeries, remains open for urgent care
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
